Galantamine on visceral fat/inflammation in metabolic syndrome
Abdominal Obesity Metabolic Syndrome
Enrolment: 60 · Results not recorded
Loading the evidence…
Drug · Acetylcholinesterase inhibitor
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Abdominal Obesity Metabolic Syndrome
Enrolment: 60 · Results not recorded
Dementia · Alzheimer's Disease
Enrolment not recorded · Results not recorded
Alzheimer Disease · Vascular Dementia
Enrolment: 593 · Results not recorded
Major Depression · Bipolar Depression
Enrolment: 39 · Results not recorded
Alzheimer's Disease · Dementia
Enrolment: 554 · Results not recorded
Schizophrenia · Schizoaffective Disorder
Enrolment: 3 · Results not recorded
Nicotine Addiction
Enrolment: 13 · Results not recorded
Alzheimer's Disease
Enrolment: 1882 · Results not recorded
Chronic Schizophrenia
Enrolment: 20 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Contusion spinal cord injury using the NYU/MASCIS impactor
Galantamine-treated rats had significantly higher BBB scores than lesion controls, a higher percentage of NFM-positive cells at 6 weeks post-injury and reduced lesion size, indicating increased tissue survival and faster hind limb motor recovery.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
Model: Experimental traumatic brain injury; injury device and severity not stated in the retrieved text
Post-injury galantamine reduced traumatic brain injury triggered blood-brain barrier permeability at 24 h and attenuated the loss of GABAergic and newborn neurons in the ipsilateral hippocampus. Hippocampal function improved, with significant gains in Morris water maze, novel object recognition and…
Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.